Response to letter regarding article, "Increased Mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery"

Circulation

Volumn 117, Issue 25, 2008, Pages

  Reeves, Barnaby C ^a   Murphy, Gavin J ^a   Rogers, Chris A ^a   Culliford, Lucy ^a   Rizvi, Syed I A ^a   Angelini, Gianni D ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ;

CLINICAL TRIAL; COHORT ANALYSIS; ERYTHROCYTE TRANSFUSION; HEALTH CARE COST; HEART MUSCLE ISCHEMIA; HEART SURGERY; HEMATOCRIT; HUMAN; INFECTION; ISCHEMIA; LETTER; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

EID: 67650576667     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.770198     Document Type: Letter

References (3)

1. Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L, Angelini GD. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation. 2007;116: 2544-2552.
2. Ferguson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussières JS, Cote D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R; BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358: 2319-2331.
3. Furnary AP, Wu Y, Hiratzka LF, Grunkemeier GL, Page US 3rd. Aprotinin does not increase the risk of renal failure in cardiac surgery patients. Circulation. 2007;116(suppl):I-127-I-133.